Helena Colom

A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach

Franc Andreu, Helena Colom, Laure Elens et al. · Clinical Pharmacokinetics · 2017 · 90 citations

Population Approach, Medicine, Physiology +4

Quality by Design approach to understand the physicochemical phenomena involved in controlled release of captopril SR matrix tablets

J. Saurí, Diana Millán, Josep M. Suñé‐Negre et al. · International Journal of Pharmaceutics · 2014 · 78 citations

Design Approach, Medicine, Pharmaceutical Technology +5

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation

Núria Lloberas, Laure Elens, Inés Llaudó et al. · Pharmacogenetics and Genomics · 2017 · 70 citations

A Comparative In Vitro Study of Transdermal Absorption of a Series of Calcium Channel Antagonists

I. Díez, Helena Colom, J.M. Moreno et al. · Journal of Pharmaceutical Sciences · 1991 · 68 citations

Calcium Channel Antagonists, Physiology, Vitro Study +3

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

Manuel Ruíz‐Borrego, Begoña Jiménez, Silvia Antolín et al. · Investigational New Drugs · 2018 · 54 citations

Phase Ib Study, Oncology, Medicine +7